nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—UGT1A1—Mycophenolic acid—systemic scleroderma	0.106	0.206	CbGbCtD
Pazopanib—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.0592	0.115	CbGbCtD
Pazopanib—ABCG2—Leflunomide—systemic scleroderma	0.0527	0.103	CbGbCtD
Pazopanib—CYP2C8—Mometasone—systemic scleroderma	0.0435	0.0848	CbGbCtD
Pazopanib—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.041	0.0798	CbGbCtD
Pazopanib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0325	0.0634	CbGbCtD
Pazopanib—CYP1A2—Pentoxifylline—systemic scleroderma	0.0228	0.0443	CbGbCtD
Pazopanib—CYP1A2—Leflunomide—systemic scleroderma	0.0217	0.0423	CbGbCtD
Pazopanib—ABCB1—Lisinopril—systemic scleroderma	0.0199	0.0388	CbGbCtD
Pazopanib—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0173	0.0338	CbGbCtD
Pazopanib—SLCO1B1—Methotrexate—systemic scleroderma	0.0164	0.032	CbGbCtD
Pazopanib—ABCB1—Captopril—systemic scleroderma	0.0149	0.029	CbGbCtD
Pazopanib—CYP2D6—Captopril—systemic scleroderma	0.014	0.0274	CbGbCtD
Pazopanib—ABCG2—Methotrexate—systemic scleroderma	0.0131	0.0254	CbGbCtD
Pazopanib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0117	0.0229	CbGbCtD
Pazopanib—ABCB1—Prednisone—systemic scleroderma	0.00938	0.0183	CbGbCtD
Pazopanib—FGF1—dermis—systemic scleroderma	0.00723	0.0601	CbGeAlD
Pazopanib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00703	0.0137	CbGbCtD
Pazopanib—KIT—myenteric nerve plexus—systemic scleroderma	0.00653	0.0543	CbGeAlD
Pazopanib—CYP3A4—Prednisone—systemic scleroderma	0.00562	0.0109	CbGbCtD
Pazopanib—ABCB1—Methotrexate—systemic scleroderma	0.00471	0.00917	CbGbCtD
Pazopanib—FLT1—umbilical vein—systemic scleroderma	0.00408	0.0339	CbGeAlD
Pazopanib—KDR—umbilical vein—systemic scleroderma	0.00345	0.0287	CbGeAlD
Pazopanib—FGF1—artery—systemic scleroderma	0.00261	0.0217	CbGeAlD
Pazopanib—FLT4—endothelium—systemic scleroderma	0.00248	0.0207	CbGeAlD
Pazopanib—FLT4—blood vessel—systemic scleroderma	0.00229	0.0191	CbGeAlD
Pazopanib—FLT1—artery—systemic scleroderma	0.00229	0.019	CbGeAlD
Pazopanib—FGF1—endothelium—systemic scleroderma	0.00221	0.0184	CbGeAlD
Pazopanib—FGF1—blood vessel—systemic scleroderma	0.00204	0.0169	CbGeAlD
Pazopanib—KDR—artery—systemic scleroderma	0.00193	0.0161	CbGeAlD
Pazopanib—FLT1—endothelium—systemic scleroderma	0.00193	0.0161	CbGeAlD
Pazopanib—MAP3K9—digestive system—systemic scleroderma	0.00184	0.0153	CbGeAlD
Pazopanib—FLT1—blood vessel—systemic scleroderma	0.00178	0.0148	CbGeAlD
Pazopanib—KDR—endothelium—systemic scleroderma	0.00163	0.0136	CbGeAlD
Pazopanib—MAP3K9—lung—systemic scleroderma	0.00153	0.0128	CbGeAlD
Pazopanib—LYN—connective tissue—systemic scleroderma	0.00151	0.0126	CbGeAlD
Pazopanib—KDR—blood vessel—systemic scleroderma	0.00151	0.0125	CbGeAlD
Pazopanib—FGFR3—connective tissue—systemic scleroderma	0.00151	0.0125	CbGeAlD
Pazopanib—KIT—endothelium—systemic scleroderma	0.00145	0.012	CbGeAlD
Pazopanib—FGFR3—skin of body—systemic scleroderma	0.00136	0.0113	CbGeAlD
Pazopanib—KIT—blood vessel—systemic scleroderma	0.00133	0.0111	CbGeAlD
Pazopanib—PDGFRB—blood vessel—systemic scleroderma	0.0013	0.0108	CbGeAlD
Pazopanib—ITK—lung—systemic scleroderma	0.00127	0.0105	CbGeAlD
Pazopanib—SH2B3—tendon—systemic scleroderma	0.00124	0.0103	CbGeAlD
Pazopanib—PI4KB—smooth muscle tissue—systemic scleroderma	0.00122	0.0101	CbGeAlD
Pazopanib—AURKC—tendon—systemic scleroderma	0.00122	0.0101	CbGeAlD
Pazopanib—TAOK1—lung—systemic scleroderma	0.00115	0.00958	CbGeAlD
Pazopanib—MAP3K2—connective tissue—systemic scleroderma	0.00111	0.00921	CbGeAlD
Pazopanib—STK16—digestive system—systemic scleroderma	0.0011	0.00919	CbGeAlD
Pazopanib—SH2B3—lung—systemic scleroderma	0.00108	0.00902	CbGeAlD
Pazopanib—STK16—tendon—systemic scleroderma	0.00105	0.00874	CbGeAlD
Pazopanib—FGF1—connective tissue—systemic scleroderma	0.00104	0.00868	CbGeAlD
Pazopanib—RIOK2—tendon—systemic scleroderma	0.00103	0.00861	CbGeAlD
Pazopanib—SH2B3—Dexamethasone—Mometasone—systemic scleroderma	0.000995	0.324	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Mometasone—systemic scleroderma	0.000995	0.324	CbGdCrCtD
Pazopanib—FGFR2—connective tissue—systemic scleroderma	0.000985	0.0082	CbGeAlD
Pazopanib—PLK4—lung—systemic scleroderma	0.000977	0.00812	CbGeAlD
Pazopanib—FGF1—smooth muscle tissue—systemic scleroderma	0.000955	0.00794	CbGeAlD
Pazopanib—FGF1—skin of body—systemic scleroderma	0.000942	0.00784	CbGeAlD
Pazopanib—STK36—tendon—systemic scleroderma	0.000929	0.00773	CbGeAlD
Pazopanib—STK16—lung—systemic scleroderma	0.000922	0.00767	CbGeAlD
Pazopanib—PI4KB—tendon—systemic scleroderma	0.000915	0.00761	CbGeAlD
Pazopanib—FLT1—connective tissue—systemic scleroderma	0.000913	0.0076	CbGeAlD
Pazopanib—RIOK2—lung—systemic scleroderma	0.000908	0.00755	CbGeAlD
Pazopanib—FGFR3—lung—systemic scleroderma	0.000908	0.00755	CbGeAlD
Pazopanib—FGFR2—smooth muscle tissue—systemic scleroderma	0.000901	0.0075	CbGeAlD
Pazopanib—MAP3K19—lung—systemic scleroderma	0.000899	0.00748	CbGeAlD
Pazopanib—BMPR1B—lung—systemic scleroderma	0.000899	0.00748	CbGeAlD
Pazopanib—FGFR2—skin of body—systemic scleroderma	0.00089	0.0074	CbGeAlD
Pazopanib—TAOK3—connective tissue—systemic scleroderma	0.000861	0.00716	CbGeAlD
Pazopanib—PDGFRA—connective tissue—systemic scleroderma	0.000856	0.00712	CbGeAlD
Pazopanib—FLT1—smooth muscle tissue—systemic scleroderma	0.000836	0.00695	CbGeAlD
Pazopanib—STK36—lung—systemic scleroderma	0.000816	0.00678	CbGeAlD
Pazopanib—EPHB6—skin of body—systemic scleroderma	0.000815	0.00678	CbGeAlD
Pazopanib—PI4KB—lung—systemic scleroderma	0.000803	0.00668	CbGeAlD
Pazopanib—PIP4K2C—tendon—systemic scleroderma	0.000803	0.00668	CbGeAlD
Pazopanib—FGFR1—tendon—systemic scleroderma	0.000797	0.00663	CbGeAlD
Pazopanib—LIMK2—lung—systemic scleroderma	0.000789	0.00656	CbGeAlD
Pazopanib—PDGFRA—smooth muscle tissue—systemic scleroderma	0.000783	0.00651	CbGeAlD
Pazopanib—KDR—connective tissue—systemic scleroderma	0.000772	0.00642	CbGeAlD
Pazopanib—FGF1—digestive system—systemic scleroderma	0.000754	0.00627	CbGeAlD
Pazopanib—CSF1R—connective tissue—systemic scleroderma	0.000754	0.00627	CbGeAlD
Pazopanib—FGFR2—digestive system—systemic scleroderma	0.000712	0.00592	CbGeAlD
Pazopanib—FLT4—lung—systemic scleroderma	0.000709	0.00589	CbGeAlD
Pazopanib—KDR—smooth muscle tissue—systemic scleroderma	0.000706	0.00588	CbGeAlD
Pazopanib—PIP4K2C—lung—systemic scleroderma	0.000705	0.00586	CbGeAlD
Pazopanib—FGFR1—lung—systemic scleroderma	0.000699	0.00581	CbGeAlD
Pazopanib—CSF1R—smooth muscle tissue—systemic scleroderma	0.000689	0.00573	CbGeAlD
Pazopanib—KIT—connective tissue—systemic scleroderma	0.000684	0.00569	CbGeAlD
Pazopanib—CSF1R—skin of body—systemic scleroderma	0.00068	0.00566	CbGeAlD
Pazopanib—PDGFRB—connective tissue—systemic scleroderma	0.000668	0.00556	CbGeAlD
Pazopanib—MAP3K2—lung—systemic scleroderma	0.000668	0.00556	CbGeAlD
Pazopanib—FLT1—digestive system—systemic scleroderma	0.00066	0.00549	CbGeAlD
Pazopanib—FGF1—lung—systemic scleroderma	0.000629	0.00524	CbGeAlD
Pazopanib—FLT1—tendon—systemic scleroderma	0.000628	0.00522	CbGeAlD
Pazopanib—KIT—smooth muscle tissue—systemic scleroderma	0.000626	0.00521	CbGeAlD
Pazopanib—LCK—lung—systemic scleroderma	0.000626	0.0052	CbGeAlD
Pazopanib—STK10—digestive system—systemic scleroderma	0.000624	0.00519	CbGeAlD
Pazopanib—TAOK3—digestive system—systemic scleroderma	0.000622	0.00517	CbGeAlD
Pazopanib—EPHB6—tendon—systemic scleroderma	0.000621	0.00516	CbGeAlD
Pazopanib—PDGFRA—digestive system—systemic scleroderma	0.000618	0.00514	CbGeAlD
Pazopanib—KIT—skin of body—systemic scleroderma	0.000618	0.00514	CbGeAlD
Pazopanib—PDGFRB—smooth muscle tissue—systemic scleroderma	0.000611	0.00509	CbGeAlD
Pazopanib—PDGFRB—skin of body—systemic scleroderma	0.000603	0.00502	CbGeAlD
Pazopanib—FGFR2—lung—systemic scleroderma	0.000594	0.00494	CbGeAlD
Pazopanib—STK10—tendon—systemic scleroderma	0.000594	0.00494	CbGeAlD
Pazopanib—TAOK3—tendon—systemic scleroderma	0.000592	0.00492	CbGeAlD
Pazopanib—UGT1A1—digestive system—systemic scleroderma	0.00059	0.00491	CbGeAlD
Pazopanib—PDGFRA—tendon—systemic scleroderma	0.000588	0.00489	CbGeAlD
Pazopanib—KDR—digestive system—systemic scleroderma	0.000558	0.00464	CbGeAlD
Pazopanib—FLT1—lung—systemic scleroderma	0.000551	0.00458	CbGeAlD
Pazopanib—EPHB6—lung—systemic scleroderma	0.000545	0.00453	CbGeAlD
Pazopanib—CSF1R—digestive system—systemic scleroderma	0.000544	0.00453	CbGeAlD
Pazopanib—SH2B3—Dexamethasone—Prednisone—systemic scleroderma	0.000542	0.176	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Prednisone—systemic scleroderma	0.000542	0.176	CbGdCrCtD
Pazopanib—MAP2K5—tendon—systemic scleroderma	0.000531	0.00441	CbGeAlD
Pazopanib—KDR—tendon—systemic scleroderma	0.000531	0.00441	CbGeAlD
Pazopanib—STK10—lung—systemic scleroderma	0.000522	0.00434	CbGeAlD
Pazopanib—TAOK3—lung—systemic scleroderma	0.00052	0.00432	CbGeAlD
Pazopanib—CSF1R—tendon—systemic scleroderma	0.000518	0.00431	CbGeAlD
Pazopanib—PDGFRA—lung—systemic scleroderma	0.000516	0.00429	CbGeAlD
Pazopanib—KIT—digestive system—systemic scleroderma	0.000494	0.00411	CbGeAlD
Pazopanib—SLCO1B1—digestive system—systemic scleroderma	0.000491	0.00408	CbGeAlD
Pazopanib—PDGFRB—digestive system—systemic scleroderma	0.000483	0.00401	CbGeAlD
Pazopanib—MAP2K5—lung—systemic scleroderma	0.000466	0.00387	CbGeAlD
Pazopanib—KDR—lung—systemic scleroderma	0.000466	0.00387	CbGeAlD
Pazopanib—PDGFRB—tendon—systemic scleroderma	0.000459	0.00382	CbGeAlD
Pazopanib—CSF1R—lung—systemic scleroderma	0.000455	0.00378	CbGeAlD
Pazopanib—KIT—lung—systemic scleroderma	0.000413	0.00343	CbGeAlD
Pazopanib—PDGFRB—lung—systemic scleroderma	0.000403	0.00335	CbGeAlD
Pazopanib—ABCB1—blood vessel—systemic scleroderma	0.000361	0.003	CbGeAlD
Pazopanib—CYP1A2—digestive system—systemic scleroderma	0.000261	0.00217	CbGeAlD
Pazopanib—ABCG2—lung—systemic scleroderma	0.000227	0.00188	CbGeAlD
Pazopanib—CYP1A2—lung—systemic scleroderma	0.000218	0.00181	CbGeAlD
Pazopanib—CYP3A4—digestive system—systemic scleroderma	0.000189	0.00157	CbGeAlD
Pazopanib—CYP2D6—digestive system—systemic scleroderma	0.000186	0.00155	CbGeAlD
Pazopanib—Anorexia—Mycophenolic acid—systemic scleroderma	0.000162	0.000795	CcSEcCtD
Pazopanib—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000162	0.000795	CcSEcCtD
Pazopanib—Insomnia—Leflunomide—systemic scleroderma	0.000161	0.000791	CcSEcCtD
Pazopanib—Abdominal distension—Prednisone—systemic scleroderma	0.000161	0.00079	CcSEcCtD
Pazopanib—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000161	0.00079	CcSEcCtD
Pazopanib—Paraesthesia—Leflunomide—systemic scleroderma	0.00016	0.000785	CcSEcCtD
Pazopanib—Chest pain—Lisinopril—systemic scleroderma	0.00016	0.000784	CcSEcCtD
Pazopanib—Myalgia—Lisinopril—systemic scleroderma	0.00016	0.000784	CcSEcCtD
Pazopanib—Arthralgia—Lisinopril—systemic scleroderma	0.00016	0.000784	CcSEcCtD
Pazopanib—Dyspnoea—Leflunomide—systemic scleroderma	0.000159	0.00078	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000159	0.000779	CcSEcCtD
Pazopanib—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000158	0.000776	CcSEcCtD
Pazopanib—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.000158	0.000775	CcSEcCtD
Pazopanib—Lethargy—Methotrexate—systemic scleroderma	0.000158	0.000775	CcSEcCtD
Pazopanib—Dyspepsia—Leflunomide—systemic scleroderma	0.000157	0.00077	CcSEcCtD
Pazopanib—Pancreatitis—Prednisone—systemic scleroderma	0.000157	0.00077	CcSEcCtD
Pazopanib—Vomiting—Mometasone—systemic scleroderma	0.000156	0.000768	CcSEcCtD
Pazopanib—Dry mouth—Lisinopril—systemic scleroderma	0.000156	0.000767	CcSEcCtD
Pazopanib—Rash—Mometasone—systemic scleroderma	0.000155	0.000762	CcSEcCtD
Pazopanib—Asthenia—Captopril—systemic scleroderma	0.000155	0.000761	CcSEcCtD
Pazopanib—Dermatitis—Mometasone—systemic scleroderma	0.000155	0.000761	CcSEcCtD
Pazopanib—Decreased appetite—Leflunomide—systemic scleroderma	0.000155	0.00076	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000155	0.00076	CcSEcCtD
Pazopanib—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000154	0.000757	CcSEcCtD
Pazopanib—Headache—Mometasone—systemic scleroderma	0.000154	0.000757	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000154	0.000755	CcSEcCtD
Pazopanib—Insomnia—Mycophenolic acid—systemic scleroderma	0.000154	0.000755	CcSEcCtD
Pazopanib—Fatigue—Leflunomide—systemic scleroderma	0.000154	0.000754	CcSEcCtD
Pazopanib—Oedema—Lisinopril—systemic scleroderma	0.000153	0.000752	CcSEcCtD
Pazopanib—Pruritus—Captopril—systemic scleroderma	0.000153	0.000751	CcSEcCtD
Pazopanib—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000153	0.000749	CcSEcCtD
Pazopanib—Pain—Leflunomide—systemic scleroderma	0.000152	0.000748	CcSEcCtD
Pazopanib—Infection—Lisinopril—systemic scleroderma	0.000152	0.000747	CcSEcCtD
Pazopanib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000152	0.000746	CcSEcCtD
Pazopanib—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000152	0.000744	CcSEcCtD
Pazopanib—Somnolence—Mycophenolic acid—systemic scleroderma	0.000151	0.000742	CcSEcCtD
Pazopanib—Shock—Lisinopril—systemic scleroderma	0.000151	0.000739	CcSEcCtD
Pazopanib—Thrombocytopenia—Lisinopril—systemic scleroderma	0.00015	0.000736	CcSEcCtD
Pazopanib—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00015	0.000735	CcSEcCtD
Pazopanib—Neutropenia—Prednisone—systemic scleroderma	0.00015	0.000734	CcSEcCtD
Pazopanib—Abdominal pain—Azathioprine—systemic scleroderma	0.000149	0.000732	CcSEcCtD
Pazopanib—Skin disorder—Lisinopril—systemic scleroderma	0.000149	0.00073	CcSEcCtD
Pazopanib—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000148	0.000727	CcSEcCtD
Pazopanib—Diarrhoea—Captopril—systemic scleroderma	0.000148	0.000726	CcSEcCtD
Pazopanib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000148	0.000725	CcSEcCtD
Pazopanib—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000724	CcSEcCtD
Pazopanib—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000722	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000147	0.00072	CcSEcCtD
Pazopanib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000147	0.000719	CcSEcCtD
Pazopanib—Nausea—Mometasone—systemic scleroderma	0.000146	0.000718	CcSEcCtD
Pazopanib—Anorexia—Lisinopril—systemic scleroderma	0.000146	0.000716	CcSEcCtD
Pazopanib—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000146	0.000715	CcSEcCtD
Pazopanib—Pain—Mycophenolic acid—systemic scleroderma	0.000145	0.000714	CcSEcCtD
Pazopanib—Weight decreased—Prednisone—systemic scleroderma	0.000145	0.00071	CcSEcCtD
Pazopanib—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000709	CcSEcCtD
Pazopanib—Cough—Mycophenolate mofetil—systemic scleroderma	0.000143	0.000704	CcSEcCtD
Pazopanib—Dizziness—Captopril—systemic scleroderma	0.000143	0.000702	CcSEcCtD
Pazopanib—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000143	0.000701	CcSEcCtD
Pazopanib—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000142	0.000697	CcSEcCtD
Pazopanib—Abdominal pain—Leflunomide—systemic scleroderma	0.000141	0.000691	CcSEcCtD
Pazopanib—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000141	0.00069	CcSEcCtD
Pazopanib—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00014	0.000687	CcSEcCtD
Pazopanib—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00014	0.000687	CcSEcCtD
Pazopanib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00014	0.000687	CcSEcCtD
Pazopanib—Myocardial infarction—Prednisone—systemic scleroderma	0.00014	0.000686	CcSEcCtD
Pazopanib—Breast disorder—Methotrexate—systemic scleroderma	0.00014	0.000686	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000139	0.000685	CcSEcCtD
Pazopanib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000139	0.000682	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000139	0.000682	CcSEcCtD
Pazopanib—Insomnia—Lisinopril—systemic scleroderma	0.000138	0.00068	CcSEcCtD
Pazopanib—Paraesthesia—Lisinopril—systemic scleroderma	0.000137	0.000675	CcSEcCtD
Pazopanib—Vomiting—Captopril—systemic scleroderma	0.000137	0.000675	CcSEcCtD
Pazopanib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000137	0.000672	CcSEcCtD
Pazopanib—Dyspnoea—Lisinopril—systemic scleroderma	0.000136	0.00067	CcSEcCtD
Pazopanib—Rash—Captopril—systemic scleroderma	0.000136	0.000669	CcSEcCtD
Pazopanib—Dermatitis—Captopril—systemic scleroderma	0.000136	0.000669	CcSEcCtD
Pazopanib—Somnolence—Lisinopril—systemic scleroderma	0.000136	0.000668	CcSEcCtD
Pazopanib—Headache—Captopril—systemic scleroderma	0.000135	0.000665	CcSEcCtD
Pazopanib—Dyspepsia—Lisinopril—systemic scleroderma	0.000135	0.000662	CcSEcCtD
Pazopanib—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000134	0.00066	CcSEcCtD
Pazopanib—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000134	0.000659	CcSEcCtD
Pazopanib—ABCB1—digestive system—systemic scleroderma	0.000134	0.00111	CbGeAlD
Pazopanib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000654	CcSEcCtD
Pazopanib—Decreased appetite—Lisinopril—systemic scleroderma	0.000133	0.000653	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000132	0.000649	CcSEcCtD
Pazopanib—Fatigue—Lisinopril—systemic scleroderma	0.000132	0.000648	CcSEcCtD
Pazopanib—Shock—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000648	CcSEcCtD
Pazopanib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000646	CcSEcCtD
Pazopanib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000131	0.000645	CcSEcCtD
Pazopanib—Pancreatitis—Methotrexate—systemic scleroderma	0.000131	0.000643	CcSEcCtD
Pazopanib—Pain—Lisinopril—systemic scleroderma	0.000131	0.000643	CcSEcCtD
Pazopanib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00013	0.00064	CcSEcCtD
Pazopanib—Bradycardia—Prednisone—systemic scleroderma	0.00013	0.00064	CcSEcCtD
Pazopanib—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00013	0.000637	CcSEcCtD
Pazopanib—Diarrhoea—Azathioprine—systemic scleroderma	0.000129	0.000634	CcSEcCtD
Pazopanib—Haemoglobin—Prednisone—systemic scleroderma	0.000129	0.000631	CcSEcCtD
Pazopanib—Nausea—Captopril—systemic scleroderma	0.000128	0.00063	CcSEcCtD
Pazopanib—Haemorrhage—Prednisone—systemic scleroderma	0.000128	0.000628	CcSEcCtD
Pazopanib—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000128	0.000628	CcSEcCtD
Pazopanib—Asthenia—Leflunomide—systemic scleroderma	0.000128	0.000628	CcSEcCtD
Pazopanib—Pruritus—Leflunomide—systemic scleroderma	0.000126	0.000619	CcSEcCtD
Pazopanib—Connective tissue disorder—Prednisone—systemic scleroderma	0.000126	0.000617	CcSEcCtD
Pazopanib—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000125	0.000615	CcSEcCtD
Pazopanib—Neutropenia—Methotrexate—systemic scleroderma	0.000125	0.000613	CcSEcCtD
Pazopanib—Dizziness—Azathioprine—systemic scleroderma	0.000125	0.000612	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000122	0.0006	CcSEcCtD
Pazopanib—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000122	0.000599	CcSEcCtD
Pazopanib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000122	0.000599	CcSEcCtD
Pazopanib—Diarrhoea—Leflunomide—systemic scleroderma	0.000122	0.000598	CcSEcCtD
Pazopanib—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000596	CcSEcCtD
Pazopanib—Abdominal pain—Lisinopril—systemic scleroderma	0.000121	0.000594	CcSEcCtD
Pazopanib—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000591	CcSEcCtD
Pazopanib—Pruritus—Mycophenolic acid—systemic scleroderma	0.00012	0.00059	CcSEcCtD
Pazopanib—Vomiting—Azathioprine—systemic scleroderma	0.00012	0.000589	CcSEcCtD
Pazopanib—Eye disorder—Prednisone—systemic scleroderma	0.00012	0.000587	CcSEcCtD
Pazopanib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000587	CcSEcCtD
Pazopanib—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000585	CcSEcCtD
Pazopanib—Infestation NOS—Methotrexate—systemic scleroderma	0.000119	0.000585	CcSEcCtD
Pazopanib—Infestation—Methotrexate—systemic scleroderma	0.000119	0.000585	CcSEcCtD
Pazopanib—Rash—Azathioprine—systemic scleroderma	0.000119	0.000584	CcSEcCtD
Pazopanib—Dermatitis—Azathioprine—systemic scleroderma	0.000119	0.000583	CcSEcCtD
Pazopanib—Flushing—Prednisone—systemic scleroderma	0.000119	0.000583	CcSEcCtD
Pazopanib—Headache—Azathioprine—systemic scleroderma	0.000118	0.00058	CcSEcCtD
Pazopanib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000118	0.00058	CcSEcCtD
Pazopanib—Dizziness—Leflunomide—systemic scleroderma	0.000118	0.000578	CcSEcCtD
Pazopanib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000572	CcSEcCtD
Pazopanib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000116	0.000571	CcSEcCtD
Pazopanib—Stomatitis—Methotrexate—systemic scleroderma	0.000116	0.00057	CcSEcCtD
Pazopanib—Angiopathy—Prednisone—systemic scleroderma	0.000116	0.00057	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000569	CcSEcCtD
Pazopanib—Pain—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000563	CcSEcCtD
Pazopanib—Haematuria—Methotrexate—systemic scleroderma	0.000114	0.000558	CcSEcCtD
Pazopanib—Vomiting—Leflunomide—systemic scleroderma	0.000113	0.000556	CcSEcCtD
Pazopanib—Alopecia—Prednisone—systemic scleroderma	0.000113	0.000555	CcSEcCtD
Pazopanib—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000113	0.000553	CcSEcCtD
Pazopanib—Dizziness—Mycophenolic acid—systemic scleroderma	0.000112	0.000552	CcSEcCtD
Pazopanib—Epistaxis—Methotrexate—systemic scleroderma	0.000112	0.000552	CcSEcCtD
Pazopanib—Rash—Leflunomide—systemic scleroderma	0.000112	0.000552	CcSEcCtD
Pazopanib—Dermatitis—Leflunomide—systemic scleroderma	0.000112	0.000551	CcSEcCtD
Pazopanib—Mental disorder—Prednisone—systemic scleroderma	0.000112	0.00055	CcSEcCtD
Pazopanib—Nausea—Azathioprine—systemic scleroderma	0.000112	0.00055	CcSEcCtD
Pazopanib—ABCB1—lung—systemic scleroderma	0.000112	0.000929	CbGeAlD
Pazopanib—Headache—Leflunomide—systemic scleroderma	0.000112	0.000548	CcSEcCtD
Pazopanib—Malnutrition—Prednisone—systemic scleroderma	0.000111	0.000547	CcSEcCtD
Pazopanib—Erythema—Prednisone—systemic scleroderma	0.000111	0.000547	CcSEcCtD
Pazopanib—Asthenia—Lisinopril—systemic scleroderma	0.00011	0.000539	CcSEcCtD
Pazopanib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00011	0.000538	CcSEcCtD
Pazopanib—Pruritus—Lisinopril—systemic scleroderma	0.000108	0.000532	CcSEcCtD
Pazopanib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000108	0.000531	CcSEcCtD
Pazopanib—Haemoglobin—Methotrexate—systemic scleroderma	0.000107	0.000528	CcSEcCtD
Pazopanib—Rash—Mycophenolic acid—systemic scleroderma	0.000107	0.000526	CcSEcCtD
Pazopanib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000107	0.000526	CcSEcCtD
Pazopanib—Haemorrhage—Methotrexate—systemic scleroderma	0.000107	0.000525	CcSEcCtD
Pazopanib—Headache—Mycophenolic acid—systemic scleroderma	0.000106	0.000523	CcSEcCtD
Pazopanib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000521	CcSEcCtD
Pazopanib—Nausea—Leflunomide—systemic scleroderma	0.000106	0.00052	CcSEcCtD
Pazopanib—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000106	0.000519	CcSEcCtD
Pazopanib—Vision blurred—Prednisone—systemic scleroderma	0.000105	0.000515	CcSEcCtD
Pazopanib—Urethral disorder—Methotrexate—systemic scleroderma	0.000105	0.000515	CcSEcCtD
Pazopanib—Diarrhoea—Lisinopril—systemic scleroderma	0.000105	0.000514	CcSEcCtD
Pazopanib—Anaemia—Prednisone—systemic scleroderma	0.000103	0.000506	CcSEcCtD
Pazopanib—Dizziness—Lisinopril—systemic scleroderma	0.000101	0.000497	CcSEcCtD
Pazopanib—Nausea—Mycophenolic acid—systemic scleroderma	0.000101	0.000496	CcSEcCtD
Pazopanib—Eye disorder—Methotrexate—systemic scleroderma	9.99e-05	0.000491	CcSEcCtD
Pazopanib—Syncope—Prednisone—systemic scleroderma	9.99e-05	0.00049	CcSEcCtD
Pazopanib—Cardiac disorder—Methotrexate—systemic scleroderma	9.93e-05	0.000487	CcSEcCtD
Pazopanib—Loss of consciousness—Prednisone—systemic scleroderma	9.79e-05	0.000481	CcSEcCtD
Pazopanib—Vomiting—Lisinopril—systemic scleroderma	9.73e-05	0.000478	CcSEcCtD
Pazopanib—Angiopathy—Methotrexate—systemic scleroderma	9.7e-05	0.000476	CcSEcCtD
Pazopanib—Rash—Lisinopril—systemic scleroderma	9.65e-05	0.000474	CcSEcCtD
Pazopanib—Dermatitis—Lisinopril—systemic scleroderma	9.64e-05	0.000473	CcSEcCtD
Pazopanib—Mediastinal disorder—Methotrexate—systemic scleroderma	9.64e-05	0.000473	CcSEcCtD
Pazopanib—Asthenia—Mycophenolate mofetil—systemic scleroderma	9.62e-05	0.000472	CcSEcCtD
Pazopanib—Hypertension—Prednisone—systemic scleroderma	9.62e-05	0.000472	CcSEcCtD
Pazopanib—Chills—Methotrexate—systemic scleroderma	9.6e-05	0.000471	CcSEcCtD
Pazopanib—Headache—Lisinopril—systemic scleroderma	9.59e-05	0.000471	CcSEcCtD
Pazopanib—Pruritus—Mycophenolate mofetil—systemic scleroderma	9.49e-05	0.000466	CcSEcCtD
Pazopanib—Arthralgia—Prednisone—systemic scleroderma	9.48e-05	0.000466	CcSEcCtD
Pazopanib—Myalgia—Prednisone—systemic scleroderma	9.48e-05	0.000466	CcSEcCtD
Pazopanib—Alopecia—Methotrexate—systemic scleroderma	9.45e-05	0.000464	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	9.42e-05	0.000462	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—systemic scleroderma	9.37e-05	0.00046	CcSEcCtD
Pazopanib—Malnutrition—Methotrexate—systemic scleroderma	9.31e-05	0.000457	CcSEcCtD
Pazopanib—Erythema—Methotrexate—systemic scleroderma	9.31e-05	0.000457	CcSEcCtD
Pazopanib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	9.18e-05	0.000451	CcSEcCtD
Pazopanib—Dysgeusia—Methotrexate—systemic scleroderma	9.12e-05	0.000448	CcSEcCtD
Pazopanib—Nausea—Lisinopril—systemic scleroderma	9.09e-05	0.000446	CcSEcCtD
Pazopanib—Oedema—Prednisone—systemic scleroderma	9.09e-05	0.000446	CcSEcCtD
Pazopanib—Infection—Prednisone—systemic scleroderma	9.03e-05	0.000443	CcSEcCtD
Pazopanib—Shock—Prednisone—systemic scleroderma	8.94e-05	0.000439	CcSEcCtD
Pazopanib—Nervous system disorder—Prednisone—systemic scleroderma	8.92e-05	0.000438	CcSEcCtD
Pazopanib—Dizziness—Mycophenolate mofetil—systemic scleroderma	8.87e-05	0.000435	CcSEcCtD
Pazopanib—Skin disorder—Prednisone—systemic scleroderma	8.83e-05	0.000434	CcSEcCtD
Pazopanib—Hyperhidrosis—Prednisone—systemic scleroderma	8.79e-05	0.000432	CcSEcCtD
Pazopanib—Vision blurred—Methotrexate—systemic scleroderma	8.77e-05	0.000431	CcSEcCtD
Pazopanib—Anorexia—Prednisone—systemic scleroderma	8.67e-05	0.000426	CcSEcCtD
Pazopanib—Anaemia—Methotrexate—systemic scleroderma	8.6e-05	0.000422	CcSEcCtD
Pazopanib—Vomiting—Mycophenolate mofetil—systemic scleroderma	8.53e-05	0.000419	CcSEcCtD
Pazopanib—Rash—Mycophenolate mofetil—systemic scleroderma	8.46e-05	0.000415	CcSEcCtD
Pazopanib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	8.45e-05	0.000415	CcSEcCtD
Pazopanib—Headache—Mycophenolate mofetil—systemic scleroderma	8.4e-05	0.000413	CcSEcCtD
Pazopanib—Leukopenia—Methotrexate—systemic scleroderma	8.33e-05	0.000409	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	8.28e-05	0.000407	CcSEcCtD
Pazopanib—Insomnia—Prednisone—systemic scleroderma	8.22e-05	0.000404	CcSEcCtD
Pazopanib—Paraesthesia—Prednisone—systemic scleroderma	8.16e-05	0.000401	CcSEcCtD
Pazopanib—Cough—Methotrexate—systemic scleroderma	8.12e-05	0.000399	CcSEcCtD
Pazopanib—Dyspepsia—Prednisone—systemic scleroderma	8e-05	0.000393	CcSEcCtD
Pazopanib—Nausea—Mycophenolate mofetil—systemic scleroderma	7.97e-05	0.000391	CcSEcCtD
Pazopanib—Chest pain—Methotrexate—systemic scleroderma	7.93e-05	0.000389	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—systemic scleroderma	7.93e-05	0.000389	CcSEcCtD
Pazopanib—Myalgia—Methotrexate—systemic scleroderma	7.93e-05	0.000389	CcSEcCtD
Pazopanib—Decreased appetite—Prednisone—systemic scleroderma	7.9e-05	0.000388	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	7.87e-05	0.000386	CcSEcCtD
Pazopanib—Fatigue—Prednisone—systemic scleroderma	7.84e-05	0.000385	CcSEcCtD
Pazopanib—Infection—Methotrexate—systemic scleroderma	7.55e-05	0.000371	CcSEcCtD
Pazopanib—Nervous system disorder—Methotrexate—systemic scleroderma	7.45e-05	0.000366	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—systemic scleroderma	7.44e-05	0.000365	CcSEcCtD
Pazopanib—Gastrointestinal pain—Prednisone—systemic scleroderma	7.43e-05	0.000365	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—systemic scleroderma	7.38e-05	0.000362	CcSEcCtD
Pazopanib—Hyperhidrosis—Methotrexate—systemic scleroderma	7.35e-05	0.000361	CcSEcCtD
Pazopanib—Anorexia—Methotrexate—systemic scleroderma	7.24e-05	0.000356	CcSEcCtD
Pazopanib—Abdominal pain—Prednisone—systemic scleroderma	7.19e-05	0.000353	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	6.92e-05	0.00034	CcSEcCtD
Pazopanib—Insomnia—Methotrexate—systemic scleroderma	6.87e-05	0.000337	CcSEcCtD
Pazopanib—Paraesthesia—Methotrexate—systemic scleroderma	6.82e-05	0.000335	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—systemic scleroderma	6.77e-05	0.000333	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—systemic scleroderma	6.75e-05	0.000332	CcSEcCtD
Pazopanib—Dyspepsia—Methotrexate—systemic scleroderma	6.69e-05	0.000328	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—systemic scleroderma	6.61e-05	0.000324	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	6.56e-05	0.000322	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—systemic scleroderma	6.55e-05	0.000322	CcSEcCtD
Pazopanib—Asthenia—Prednisone—systemic scleroderma	6.52e-05	0.00032	CcSEcCtD
Pazopanib—Pain—Methotrexate—systemic scleroderma	6.5e-05	0.000319	CcSEcCtD
Pazopanib—Pruritus—Prednisone—systemic scleroderma	6.43e-05	0.000316	CcSEcCtD
Pazopanib—Diarrhoea—Prednisone—systemic scleroderma	6.22e-05	0.000305	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methotrexate—systemic scleroderma	6.21e-05	0.000305	CcSEcCtD
Pazopanib—Dizziness—Prednisone—systemic scleroderma	6.01e-05	0.000295	CcSEcCtD
Pazopanib—Abdominal pain—Methotrexate—systemic scleroderma	6.01e-05	0.000295	CcSEcCtD
Pazopanib—Vomiting—Prednisone—systemic scleroderma	5.78e-05	0.000284	CcSEcCtD
Pazopanib—Rash—Prednisone—systemic scleroderma	5.73e-05	0.000281	CcSEcCtD
Pazopanib—Dermatitis—Prednisone—systemic scleroderma	5.73e-05	0.000281	CcSEcCtD
Pazopanib—Headache—Prednisone—systemic scleroderma	5.7e-05	0.00028	CcSEcCtD
Pazopanib—Asthenia—Methotrexate—systemic scleroderma	5.45e-05	0.000268	CcSEcCtD
Pazopanib—Nausea—Prednisone—systemic scleroderma	5.4e-05	0.000265	CcSEcCtD
Pazopanib—Pruritus—Methotrexate—systemic scleroderma	5.38e-05	0.000264	CcSEcCtD
Pazopanib—Diarrhoea—Methotrexate—systemic scleroderma	5.2e-05	0.000255	CcSEcCtD
Pazopanib—Dizziness—Methotrexate—systemic scleroderma	5.02e-05	0.000247	CcSEcCtD
Pazopanib—Vomiting—Methotrexate—systemic scleroderma	4.83e-05	0.000237	CcSEcCtD
Pazopanib—Rash—Methotrexate—systemic scleroderma	4.79e-05	0.000235	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—systemic scleroderma	4.79e-05	0.000235	CcSEcCtD
Pazopanib—Headache—Methotrexate—systemic scleroderma	4.76e-05	0.000234	CcSEcCtD
Pazopanib—Nausea—Methotrexate—systemic scleroderma	4.51e-05	0.000222	CcSEcCtD
Pazopanib—MAP2K5—Signaling Pathways—CSK—systemic scleroderma	3.14e-05	0.000197	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CSK—systemic scleroderma	3.13e-05	0.000196	CbGpPWpGaD
Pazopanib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	3.08e-05	0.000193	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IRF5—systemic scleroderma	3.08e-05	0.000193	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—TNFAIP3—systemic scleroderma	3.06e-05	0.000192	CbGpPWpGaD
Pazopanib—LYN—Immune System—CSK—systemic scleroderma	3.06e-05	0.000192	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CSK—systemic scleroderma	3.06e-05	0.000191	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—TNFAIP3—systemic scleroderma	3.06e-05	0.000191	CbGpPWpGaD
Pazopanib—LYN—Axon guidance—MMP2—systemic scleroderma	3.04e-05	0.00019	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—BLK—systemic scleroderma	3.03e-05	0.00019	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—IL1A—systemic scleroderma	3.03e-05	0.000189	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—HLA-DQB1—systemic scleroderma	3.02e-05	0.000189	CbGpPWpGaD
Pazopanib—FGFR1—Disease—CD247—systemic scleroderma	3.02e-05	0.000189	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HSPG2—systemic scleroderma	3.02e-05	0.000189	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—BLK—systemic scleroderma	3.02e-05	0.000189	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—CD247—systemic scleroderma	3.01e-05	0.000189	CbGpPWpGaD
Pazopanib—LYN—Immune System—IRF5—systemic scleroderma	3.01e-05	0.000189	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—CD40LG—systemic scleroderma	3.01e-05	0.000188	CbGpPWpGaD
Pazopanib—LCK—Disease—TGFBI—systemic scleroderma	3.01e-05	0.000188	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HSPG2—systemic scleroderma	2.99e-05	0.000187	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—HLA-DQB1—systemic scleroderma	2.96e-05	0.000186	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—CTLA4—systemic scleroderma	2.95e-05	0.000185	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IRF8—systemic scleroderma	2.94e-05	0.000184	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—ITGAM—systemic scleroderma	2.94e-05	0.000184	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CD247—systemic scleroderma	2.94e-05	0.000184	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CSK—systemic scleroderma	2.92e-05	0.000183	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—CSK—systemic scleroderma	2.89e-05	0.000181	CbGpPWpGaD
Pazopanib—LYN—Immune System—IRF8—systemic scleroderma	2.88e-05	0.00018	CbGpPWpGaD
Pazopanib—LYN—Immune System—CD247—systemic scleroderma	2.88e-05	0.00018	CbGpPWpGaD
Pazopanib—LYN—Immune System—ITGAM—systemic scleroderma	2.88e-05	0.00018	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SMAD7—systemic scleroderma	2.87e-05	0.00018	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—CD40LG—systemic scleroderma	2.86e-05	0.000179	CbGpPWpGaD
Pazopanib—ITK—Immune System—IL1B—systemic scleroderma	2.81e-05	0.000176	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SMAD7—systemic scleroderma	2.81e-05	0.000176	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—CD40LG—systemic scleroderma	2.8e-05	0.000175	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—TNFAIP3—systemic scleroderma	2.75e-05	0.000172	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—MMP1—systemic scleroderma	2.75e-05	0.000172	CbGpPWpGaD
Pazopanib—LYN—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	2.72e-05	0.000171	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—BLK—systemic scleroderma	2.72e-05	0.00017	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—CD247—systemic scleroderma	2.71e-05	0.00017	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.71e-05	0.00017	CbGpPWpGaD
Pazopanib—LYN—Immune System—TNFAIP3—systemic scleroderma	2.7e-05	0.000169	CbGpPWpGaD
Pazopanib—LYN—Immune System—BLK—systemic scleroderma	2.66e-05	0.000167	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—MMP9—systemic scleroderma	2.66e-05	0.000167	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—CTLA4—systemic scleroderma	2.66e-05	0.000167	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—RHOB—systemic scleroderma	2.65e-05	0.000166	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HLA-DQB1—systemic scleroderma	2.65e-05	0.000166	CbGpPWpGaD
Pazopanib—KIT—Immune System—CTLA4—systemic scleroderma	2.61e-05	0.000164	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—RHOB—systemic scleroderma	2.6e-05	0.000163	CbGpPWpGaD
Pazopanib—FGFR1—Axon guidance—MMP9—systemic scleroderma	2.6e-05	0.000163	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—CCL2—systemic scleroderma	2.58e-05	0.000162	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—EDN1—systemic scleroderma	2.58e-05	0.000161	CbGpPWpGaD
Pazopanib—LYN—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.56e-05	0.00016	CbGpPWpGaD
Pazopanib—KDR—Developmental Biology—MMP9—systemic scleroderma	2.52e-05	0.000158	CbGpPWpGaD
Pazopanib—FGF1—Immune System—IL1A—systemic scleroderma	2.51e-05	0.000157	CbGpPWpGaD
Pazopanib—LCK—Immune System—CSK—systemic scleroderma	2.51e-05	0.000157	CbGpPWpGaD
Pazopanib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	2.5e-05	0.000157	CbGpPWpGaD
Pazopanib—FGF1—Immune System—CD40LG—systemic scleroderma	2.5e-05	0.000157	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HSPG2—systemic scleroderma	2.5e-05	0.000157	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CTLA4—systemic scleroderma	2.48e-05	0.000155	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CTLA4—systemic scleroderma	2.47e-05	0.000155	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—RHOB—systemic scleroderma	2.47e-05	0.000155	CbGpPWpGaD
Pazopanib—LCK—Immune System—IRF5—systemic scleroderma	2.47e-05	0.000155	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—MMP2—systemic scleroderma	2.47e-05	0.000154	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—RHOB—systemic scleroderma	2.46e-05	0.000154	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HSPG2—systemic scleroderma	2.45e-05	0.000154	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HLA-DQB1—systemic scleroderma	2.43e-05	0.000152	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CSK—systemic scleroderma	2.41e-05	0.000151	CbGpPWpGaD
Pazopanib—LCK—Disease—HSPG2—systemic scleroderma	2.4e-05	0.00015	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CSK—systemic scleroderma	2.37e-05	0.000148	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—CCL2—systemic scleroderma	2.36e-05	0.000148	CbGpPWpGaD
Pazopanib—LCK—Immune System—IRF8—systemic scleroderma	2.36e-05	0.000148	CbGpPWpGaD
Pazopanib—LCK—Immune System—ITGAM—systemic scleroderma	2.36e-05	0.000148	CbGpPWpGaD
Pazopanib—LCK—Immune System—CD247—systemic scleroderma	2.36e-05	0.000148	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HSPG2—systemic scleroderma	2.33e-05	0.000146	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HSPG2—systemic scleroderma	2.32e-05	0.000146	CbGpPWpGaD
Pazopanib—LCK—Disease—CSK—systemic scleroderma	2.32e-05	0.000145	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SMAD7—systemic scleroderma	2.3e-05	0.000144	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—NOS3—systemic scleroderma	2.3e-05	0.000144	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—HSPG2—systemic scleroderma	2.29e-05	0.000144	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—CD40LG—systemic scleroderma	2.29e-05	0.000144	CbGpPWpGaD
Pazopanib—LYN—Axon guidance—MMP9—systemic scleroderma	2.29e-05	0.000143	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—MMP1—systemic scleroderma	2.25e-05	0.000141	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CSK—systemic scleroderma	2.25e-05	0.000141	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CSK—systemic scleroderma	2.24e-05	0.000141	CbGpPWpGaD
Pazopanib—LCK—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	2.23e-05	0.00014	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CTLA4—systemic scleroderma	2.23e-05	0.00014	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—RHOB—systemic scleroderma	2.22e-05	0.000139	CbGpPWpGaD
Pazopanib—LCK—Immune System—TNFAIP3—systemic scleroderma	2.21e-05	0.000138	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—TGFB1—systemic scleroderma	2.19e-05	0.000137	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HLA-DQB1—systemic scleroderma	2.19e-05	0.000137	CbGpPWpGaD
Pazopanib—LCK—Immune System—BLK—systemic scleroderma	2.18e-05	0.000137	CbGpPWpGaD
Pazopanib—LYN—Immune System—CTLA4—systemic scleroderma	2.18e-05	0.000137	CbGpPWpGaD
Pazopanib—LCK—Disease—CD247—systemic scleroderma	2.18e-05	0.000136	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—RHOB—systemic scleroderma	2.17e-05	0.000136	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—MMP2—systemic scleroderma	2.17e-05	0.000136	CbGpPWpGaD
Pazopanib—KIT—Immune System—HLA-DQB1—systemic scleroderma	2.15e-05	0.000135	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—NOS3—systemic scleroderma	2.1e-05	0.000132	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—HSPG2—systemic scleroderma	2.1e-05	0.000132	CbGpPWpGaD
Pazopanib—LCK—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.1e-05	0.000131	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HSPG2—systemic scleroderma	2.09e-05	0.000131	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL1A—systemic scleroderma	2.08e-05	0.00013	CbGpPWpGaD
Pazopanib—KDR—Developmental Biology—TGFB1—systemic scleroderma	2.08e-05	0.00013	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—CD40LG—systemic scleroderma	2.07e-05	0.00013	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.06e-05	0.000129	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HSPG2—systemic scleroderma	2.05e-05	0.000128	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL1A—systemic scleroderma	2.04e-05	0.000128	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HLA-DQB1—systemic scleroderma	2.04e-05	0.000128	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HLA-DQB1—systemic scleroderma	2.04e-05	0.000128	CbGpPWpGaD
Pazopanib—KIT—Immune System—CD40LG—systemic scleroderma	2.03e-05	0.000127	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CSK—systemic scleroderma	2.02e-05	0.000127	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—NOS3—systemic scleroderma	1.99e-05	0.000125	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CSK—systemic scleroderma	1.98e-05	0.000124	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—EDN1—systemic scleroderma	1.97e-05	0.000123	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—HSPG2—systemic scleroderma	1.95e-05	0.000122	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL1A—systemic scleroderma	1.94e-05	0.000121	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL1A—systemic scleroderma	1.93e-05	0.000121	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CD40LG—systemic scleroderma	1.93e-05	0.000121	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CD40LG—systemic scleroderma	1.92e-05	0.00012	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.89e-05	0.000118	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—MMP9—systemic scleroderma	1.85e-05	0.000116	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—MMP9—systemic scleroderma	1.85e-05	0.000116	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HLA-DQB1—systemic scleroderma	1.83e-05	0.000115	CbGpPWpGaD
Pazopanib—LYN—Immune System—HLA-DQB1—systemic scleroderma	1.8e-05	0.000113	CbGpPWpGaD
Pazopanib—LCK—Immune System—CTLA4—systemic scleroderma	1.79e-05	0.000112	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—RHOB—systemic scleroderma	1.78e-05	0.000112	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—CCL2—systemic scleroderma	1.76e-05	0.00011	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—EDN1—systemic scleroderma	1.76e-05	0.00011	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL1A—systemic scleroderma	1.74e-05	0.000109	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—CTGF—systemic scleroderma	1.74e-05	0.000109	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CD40LG—systemic scleroderma	1.73e-05	0.000109	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—EDN1—systemic scleroderma	1.71e-05	0.000107	CbGpPWpGaD
Pazopanib—FGFR3—Disease—NOS3—systemic scleroderma	1.71e-05	0.000107	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL1A—systemic scleroderma	1.71e-05	0.000107	CbGpPWpGaD
Pazopanib—LYN—Immune System—CD40LG—systemic scleroderma	1.7e-05	0.000106	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—MMP9—systemic scleroderma	1.69e-05	0.000106	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HSPG2—systemic scleroderma	1.68e-05	0.000105	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—EDN1—systemic scleroderma	1.64e-05	0.000102	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—NOS3—systemic scleroderma	1.63e-05	0.000102	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—MMP9—systemic scleroderma	1.63e-05	0.000102	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CSK—systemic scleroderma	1.62e-05	0.000102	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—CTGF—systemic scleroderma	1.59e-05	9.98e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—IL1B—systemic scleroderma	1.58e-05	9.88e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—NOS3—systemic scleroderma	1.57e-05	9.83e-05	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—TGFB1—systemic scleroderma	1.53e-05	9.57e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—TGFB1—systemic scleroderma	1.52e-05	9.53e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—CTGF—systemic scleroderma	1.47e-05	9.24e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—HLA-DQB1—systemic scleroderma	1.47e-05	9.22e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.43e-05	8.95e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—NOS3—systemic scleroderma	1.42e-05	8.91e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL1A—systemic scleroderma	1.4e-05	8.76e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—TGFB1—systemic scleroderma	1.39e-05	8.71e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CD40LG—systemic scleroderma	1.39e-05	8.71e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EDN1—systemic scleroderma	1.35e-05	8.48e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—CCL2—systemic scleroderma	1.34e-05	8.42e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—TGFB1—systemic scleroderma	1.34e-05	8.42e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EDN1—systemic scleroderma	1.33e-05	8.32e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—TGFB1—systemic scleroderma	1.32e-05	8.26e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—IL1B—systemic scleroderma	1.31e-05	8.21e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EDN1—systemic scleroderma	1.26e-05	7.9e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—MMP9—systemic scleroderma	1.26e-05	7.89e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EDN1—systemic scleroderma	1.26e-05	7.88e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.23e-05	7.73e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—HSPG2—systemic scleroderma	1.21e-05	7.56e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CCL2—systemic scleroderma	1.2e-05	7.53e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—NOS3—systemic scleroderma	1.2e-05	7.51e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—NOS3—systemic scleroderma	1.18e-05	7.37e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CCL2—systemic scleroderma	1.17e-05	7.34e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—NOS3—systemic scleroderma	1.16e-05	7.24e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EDN1—systemic scleroderma	1.13e-05	7.1e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—TGFB1—systemic scleroderma	1.13e-05	7.09e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CCL2—systemic scleroderma	1.12e-05	7e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EDN1—systemic scleroderma	1.11e-05	6.95e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—NOS3—systemic scleroderma	1.1e-05	6.87e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—NOS3—systemic scleroderma	1.09e-05	6.86e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL1B—systemic scleroderma	1.09e-05	6.8e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TGFB1—systemic scleroderma	1.08e-05	6.77e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—NOS3—systemic scleroderma	1.07e-05	6.71e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL1B—systemic scleroderma	1.07e-05	6.67e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.05e-05	6.59e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—NOS3—systemic scleroderma	1.04e-05	6.54e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TGFB1—systemic scleroderma	1.04e-05	6.5e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL1B—systemic scleroderma	1.01e-05	6.33e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL1B—systemic scleroderma	1.01e-05	6.32e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—NOS3—systemic scleroderma	9.96e-06	6.24e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—HSPG2—systemic scleroderma	9.92e-06	6.21e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—NOS3—systemic scleroderma	9.86e-06	6.18e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MMP9—systemic scleroderma	9.62e-06	6.02e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—TGFB1—systemic scleroderma	9.41e-06	5.89e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCL2—systemic scleroderma	9.25e-06	5.79e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CTGF—systemic scleroderma	9.15e-06	5.73e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EDN1—systemic scleroderma	9.09e-06	5.7e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL1B—systemic scleroderma	9.09e-06	5.69e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCL2—systemic scleroderma	9.08e-06	5.69e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL1B—systemic scleroderma	8.9e-06	5.57e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCL2—systemic scleroderma	8.62e-06	5.4e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCL2—systemic scleroderma	8.6e-06	5.39e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MMP9—systemic scleroderma	8.6e-06	5.38e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HSPG2—systemic scleroderma	8.4e-06	5.26e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MMP9—systemic scleroderma	8.38e-06	5.25e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NOS3—systemic scleroderma	8.24e-06	5.16e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NOS3—systemic scleroderma	8.1e-06	5.07e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MMP9—systemic scleroderma	7.99e-06	5.01e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CTGF—systemic scleroderma	7.97e-06	4.99e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TGFB1—systemic scleroderma	7.93e-06	4.96e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—NOS3—systemic scleroderma	7.91e-06	4.96e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—TGFB1—systemic scleroderma	7.79e-06	4.88e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCL2—systemic scleroderma	7.75e-06	4.85e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NOS3—systemic scleroderma	7.68e-06	4.81e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NOS3—systemic scleroderma	7.66e-06	4.8e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—TGFB1—systemic scleroderma	7.65e-06	4.79e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCL2—systemic scleroderma	7.59e-06	4.75e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—NOS3—systemic scleroderma	7.57e-06	4.74e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CTGF—systemic scleroderma	7.51e-06	4.71e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL1B—systemic scleroderma	7.29e-06	4.57e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—TGFB1—systemic scleroderma	7.26e-06	4.54e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—TGFB1—systemic scleroderma	7.24e-06	4.53e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TGFB1—systemic scleroderma	7.09e-06	4.44e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—NOS3—systemic scleroderma	6.93e-06	4.34e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NOS3—systemic scleroderma	6.91e-06	4.33e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TGFB1—systemic scleroderma	6.91e-06	4.33e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NOS3—systemic scleroderma	6.76e-06	4.23e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MMP9—systemic scleroderma	6.61e-06	4.14e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TGFB1—systemic scleroderma	6.59e-06	4.13e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—TGFB1—systemic scleroderma	6.52e-06	4.08e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MMP9—systemic scleroderma	6.5e-06	4.07e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	6.48e-06	4.06e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—NOS3—systemic scleroderma	6.42e-06	4.02e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CTGF—systemic scleroderma	6.37e-06	3.99e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCL2—systemic scleroderma	6.22e-06	3.89e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MMP9—systemic scleroderma	6.17e-06	3.86e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MMP9—systemic scleroderma	6.15e-06	3.85e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NOS3—systemic scleroderma	5.54e-06	3.47e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MMP9—systemic scleroderma	5.54e-06	3.47e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TGFB1—systemic scleroderma	5.45e-06	3.41e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP9—systemic scleroderma	5.42e-06	3.4e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TGFB1—systemic scleroderma	5.35e-06	3.35e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—TGFB1—systemic scleroderma	5.23e-06	3.28e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TGFB1—systemic scleroderma	5.08e-06	3.18e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TGFB1—systemic scleroderma	5.07e-06	3.17e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CTGF—systemic scleroderma	4.91e-06	3.08e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TGFB1—systemic scleroderma	4.57e-06	2.86e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TGFB1—systemic scleroderma	4.47e-06	2.8e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP9—systemic scleroderma	4.45e-06	2.78e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—NOS3—systemic scleroderma	3.98e-06	2.5e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TGFB1—systemic scleroderma	3.66e-06	2.3e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—NOS3—systemic scleroderma	3.47e-06	2.17e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—NOS3—systemic scleroderma	3.27e-06	2.05e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—NOS3—systemic scleroderma	2.77e-06	1.74e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NOS3—systemic scleroderma	2.14e-06	1.34e-05	CbGpPWpGaD
